PRF Technologies (PRFX) Total Non-Current Liabilities (2019 - 2025)
PRF Technologies (PRFX) recorded quarterly Total Non-Current Liabilities of $267000.0 in Q4 2025, up 1.52% on a QoQ basis from $263000.0 in Q2 2025, and up 3.09% year-over-year from $259000.0 in Q4 2024.
PRF Technologies (PRFX) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
PRF Technologies has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $267000.0 for Q4 2025.
- Quarterly Total Non-Current Liabilities rose 3.09% year-over-year to $267000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $267000.0 (up 3.09% YoY) and the FY2025 annual result came in at $267000.0, up 3.09% from the prior year.
- Total Non-Current Liabilities climbed to $267000.0 in Q4 2025, from $263000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.2 million in Q3 2023 and troughed at $213000.0 in Q1 2021.
- A 5-year average of $386000.0 and a median of $257000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 367.08% — and 2024, when it tumbled 77.18%.
- Tracing PRFX's Total Non-Current Liabilities over 5 years: stood at $234000.0 in 2021, then grew by 3.85% to $243000.0 in 2022, then jumped by 367.08% to $1.1 million in 2023, then slumped by 77.18% to $259000.0 in 2024, then climbed by 3.09% to $267000.0 in 2025.
- Business Quant data shows PRFX's Total Non-Current Liabilities at $267000.0 in Q4 2025, $263000.0 in Q2 2025, and $259000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | PRF Technologies | 933,081.16 | -2.46 Mn | - | 267,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 267,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Dec 31, 2024 | 259,000.00 |
| Jun 30, 2024 | 257,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.15 Mn |
| Jun 30, 2023 | 247,000.00 |
| Mar 31, 2023 | 245,000.00 |
| Dec 31, 2022 | 243,000.00 |
| Mar 31, 2022 | 236,000.00 |
| Dec 31, 2021 | 234,000.00 |
| Mar 31, 2021 | 213,000.00 |
| Dec 31, 2020 | 220,000.00 |
| Jun 30, 2020 | 1.51 Mn |
| Dec 31, 2019 | 447,000.00 |